pharmaphorum April 22, 2024
Ireland’s SynOx Therapeutics has completed a second-round financing, raising $75 million, as it prepares to take its drug for tenosynovial giant cell tumour (TGCT) into phase 3 trials.
TGCT is a rare disease affecting the joints and tendons caused by overproduction of the protein CSF-1, which stimulates the proliferation of various cell types, inflammation, and destruction of the matrix of the joint.
That in turn leads to joint pain, swelling, stiffness, and limited range of motion which, while not life-threatening, can be highly debilitating to patients and affect their quality of life.
The biotech is hoping to provide an alternative to Daiichi Sankyo’s Turalio (pexidartinib), an oral CSF-1, KIT, and FLT3 inhibitor, which was given the green light by the...
Today's Sponsors
Today's Sponsor